ARS Pharmaceuticals, Inc. (SPRY)
(Delayed Data from NSDQ)
$13.33 USD
-0.21 (-1.55%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $13.36 +0.03 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for ARS Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -54.37 | -34.68 | -89.48 | -32.95 | -23.97 |
Depreciation/Amortization & Depletion | -6.81 | 0.32 | 0.79 | 0.67 | 0.62 |
Net Change from Assets/Liabilities | -7.33 | -12.75 | 1.60 | -2.63 | 3.30 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 9.24 | 7.04 | 20.33 | 3.71 | 1.15 |
Net Cash From Operating Activities | -59.27 | -40.08 | -66.76 | -31.20 | -18.90 |
Property & Equipment | -0.18 | -0.20 | -1.37 | -0.92 | -0.10 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -87.01 | 0.00 | -65.11 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -87.18 | -0.20 | -66.48 | -0.92 | -0.10 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 6.90 | 0.57 | 1.46 | 411.81 | 10.02 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | -8.68 | -0.85 | -0.70 | -1.40 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 198.84 | 0.00 | -2.61 | -0.01 |
Net Cash from Financing Activities | 6.90 | 190.73 | 0.61 | 408.51 | 8.61 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -139.55 | 150.46 | -132.62 | 376.39 | -10.38 |
Cash at Beginning of Period | 210.52 | 60.06 | 386.92 | 10.53 | 20.91 |
Cash at End of Period | 70.97 | 210.52 | 254.30 | 386.92 | 10.53 |
Diluted Net EPS | -0.57 | -0.87 | -2.56 | -11.33 | NA |
Fiscal Year End for ARS Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -22.81 | -10.29 | -54.37 | -47.20 | -32.33 |
Depreciation/Amortization & Depletion | -3.86 | -1.97 | -6.81 | -5.06 | -3.52 |
Net Change from Assets/Liabilities | 5.99 | 2.24 | -7.33 | 3.44 | 2.41 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 6.68 | 3.32 | 9.24 | 6.96 | 4.35 |
Net Cash From Operating Activities | -13.99 | -6.71 | -59.27 | -41.86 | -29.10 |
Property & Equipment | -0.12 | -0.08 | -0.18 | -0.27 | -0.22 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -21.04 | -8.43 | -87.01 | -112.95 | -66.35 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -21.16 | -8.51 | -87.18 | -113.22 | -66.58 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.80 | 0.26 | 6.90 | 5.09 | 4.17 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.80 | 0.26 | 6.90 | 5.09 | 4.17 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -34.35 | -14.97 | -139.55 | -149.99 | -91.50 |
Cash at Beginning of Period | 70.97 | 70.97 | 210.52 | 210.52 | 210.52 |
Cash at End of Period | 36.63 | 56.01 | 70.97 | 60.53 | 119.02 |
Diluted Net EPS | -0.13 | -0.11 | -0.07 | -0.16 | -0.18 |